Nevertheless, in a phase I/II study, KY1044 (anti-ICOS Ab), ICOS antagonists showed good tolerability both as single agents and combined with atezolizumab in solid tumors, including NSCLC [143]. Here, ICOS is linked to non-small cell lung carcinoma.